Advertisement
Advertisement
TRDA
Entrada Therapeutics, Inc. Common Stock
5.25
USDSponsored
+0.56
+11.94%
Nov 10, 15:59 UTC -5
Closed
After-Market
5.25
0.00
0.00%
Entrada Therapeutics, Inc. Common Stock (TRDA) Earnings
TRDA Earnings Reports
Positive Surprise Ratio
TRDA beat 12 of 21 last estimates.
57%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$7.62M
/-$1.04
Implied change from Q3 26 (Revenue/ EPS)
+741.73%
/+10.64%
Implied change from Q4 25 (Revenue/ EPS)
+486.43%
/+10.64%
Entrada Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, TRDA reported earnings of -0.94 USD per share (EPS) for Q3 26, beating the estimate of -1.03 USD, resulting in a 9.01% surprise. Revenue reached 905.00 thousand, compared to an expected 5.99 million, with a -84.89% difference. The market reacted with a -10.08% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 6 analysts forecast an EPS of -1.04 USD, with revenue projected to reach 7.62 million USD, implying an increase of 10.64% EPS, and increase of 741.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Entrada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Entrada Therapeutics, Inc. Common Stock reported EPS of -$0.94, beating estimates by 9.01%, and revenue of $905.00K, -84.89% below expectations.
How did the market react to Entrada Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -10.08%, changed from $5.06 before the earnings release to $4.55 the day after.
When is Entrada Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Entrada Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Entrada Therapeutics, Inc. Common Stock is expected to report EPS of -$1.04 and revenue of $7.62M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.